A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.
Neuroendocrine Tumors
DRUG: Octreotide|DRUG: LAR Lanreotide|BEHAVIORAL: Questionnaires
Mean Pain Scores at 3 Months, Patients will rate, on a numeric scale of 0 to 10, with 0 being No pain" to 10 being "Worst pain ever" the pain or discomfort experienced with the SSA injection., 3 months
This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.